|
|
Volumn 6, Issue 6, 2006, Pages 577-579
|
|
A better understanding of the pathophysiology of obesity and type 2 diabetes: a clue for new therapeutic approaches
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2,4 THIAZOLIDINEDIONE DERIVATIVE;
ADIPOCYTOKINE;
ADIPONECTIN;
CANNABINOID 1 RECEPTOR ANTAGONIST;
CANNABINOID RECEPTOR ANTAGONIST;
DIPEPTIDYL PEPTIDASE IV INHIBITOR;
ENDOCANNABINOID;
GLUCAGON LIKE PEPTIDE 1;
GLUCAGON LIKE PEPTIDE 1 RECEPTOR STIMULATING AGENT;
HORMONE RECEPTOR STIMULATING AGENT;
INCRETIN;
INSULIN;
LEPTIN;
METFORMIN;
NEW DRUG;
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST;
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST;
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;
RIMONABANT;
SOMATOMEDIN C;
UNCLASSIFIED DRUG;
BODY WEIGHT DISORDER;
DRUG ACTIVITY;
DRUG EFFICACY;
DRUG TARGETING;
EDEMA;
EDITORIAL;
ENERGY METABOLISM;
FOOD INTAKE;
GLUCOSE HOMEOSTASIS;
GLUCOSE METABOLISM;
HEART PROTECTION;
HUMAN;
INSULIN RESISTANCE;
INSULIN SENSITIVITY;
LIPID METABOLISM;
NON INSULIN DEPENDENT DIABETES MELLITUS;
OBESITY;
PATHOPHYSIOLOGY;
PRIORITY JOURNAL;
WEIGHT GAIN;
|
|
EID: 33750503842
PISSN: 14714892
EISSN: None
Source Type: Journal
DOI: 10.1016/j.coph.2006.09.003 Document Type: Editorial |
|
Times cited : (5)
|
|
References (0)
|
